The CBER Biologics Effectiveness and Safety (BEST) Initiative #3: Data Sources for Surveillance of Biologics (BEST 3)

This solicitation seeks proposals for multiple Indefinite Delivery/Indefinite Quantity contracts to provide the Food and Drug Administration's Center for Biologics Evaluation and Research with access to large-scale administrative claims data sources and electronic health records on patients, as well as the ability to review full medical charts, to support the Biologics Effectiveness and Safety Initiative #3. Evaluation will consider technical approach, past performance, and price/cost factors, with proposals due by July 23, 2020. A guaranteed minimum value of $10,000 and maximum total contract value of $50 million is estimated over five one-year ordering periods to be issued on a firm-fixed-price, time-and-materials, labor hour, or hybrid basis.

There is no set-aside designation. The primary NAICS code is 541715 and PSC code R425. The solicitation seeks to expand upon existing data sources and tasks the incumbent contractors with providing administrative claims data on tens of millions of U.S. patients from a distributed data network with quarterly refreshes. Performance will take place in the District of Columbia, Maryland, and Virginia over five years. The first task order requires a claims data source population of tens of millions of patients to be provided within twelve months of contract award.